{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:43:49Z","timestamp":1794098629192,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15056-y","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T20:35:44Z","timestamp":1755722144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes"],"prefix":"10.1038","volume":"15","author":[{"given":"Meng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"3","key":"15056_CR1","doi-asserted-by":"publisher","first-page":"e0121323","DOI":"10.1371\/journal.pone.0121323","volume":"10","author":"R Meza","year":"2015","unstructured":"Meza, R. et al. Lung cancer incidence trends by gender, race and histology in the united states, 1973\u20132010. PLoS One. 10 (3), e0121323 (2015).","journal-title":"PLoS One"},{"issue":"14","key":"15056_CR2","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"YL Wu","year":"2024","unstructured":"Wu, Y. L. et al. Alectinib in resected ALK-Positive Non-Small-Cell lung cancer. N Engl. J. Med. 390 (14), 1265\u20131276 (2024).","journal-title":"N Engl. J. Med."},{"issue":"11","key":"15056_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow, J. & Bivona, T. G. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer. 17 (11), 637\u2013658 (2017).","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"15056_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8 (6), 378\u2013382 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"15056_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","volume":"13","author":"P Iyengar","year":"2023","unstructured":"Iyengar, P. et al. Treatment of oligometastatic Non-Small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline. Pract. Radiat. Oncol. 13 (5), 393\u2013412 (2023).","journal-title":"Pract. Radiat. Oncol."},{"issue":"4","key":"15056_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","volume":"88","author":"GN Gan","year":"2014","unstructured":"Gan, G. N. et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving Crizotinib. Int. J. Radiat. Oncol. Biol. Phys. 88 (4), 892\u2013898 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"15056_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"XS Wang","year":"2023","unstructured":"Wang, X. S. et al. Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer. J. Natl. Cancer Inst. 115 (6), 742\u2013748 (2023).","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"15056_CR8","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","volume":"7","author":"AJ Weickhardt","year":"2012","unstructured":"Weickhardt, A. J. et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol. 7 (12), 1807\u20131814 (2012).","journal-title":"J. Thorac. Oncol."},{"issue":"33","key":"15056_CR9","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.2217\/fon-2019-0349","volume":"15","author":"S Rossi","year":"2019","unstructured":"Rossi, S. et al. Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncol. 15 (33), 3775\u20133782 (2019).","journal-title":"Future Oncol."},{"issue":"9","key":"15056_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","volume":"13","author":"Q Xu","year":"2018","unstructured":"Xu, Q. et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with First-Line EGFR-TKIs. J. Thorac. Oncol. 13 (9), 1383\u20131392 (2018).","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"15056_CR11","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","volume":"10","author":"H Al-Halabi","year":"2015","unstructured":"Al-Halabi, H. et al. Pattern of failure analysis in metastatic EGFR-Mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J. Thorac. Oncol. 10 (11), 1601\u20131607 (2015).","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"15056_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.lungcan.2015.09.025","volume":"90","author":"T Yoshida","year":"2015","unstructured":"Yoshida, T. et al. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer. 90 (3), 477\u2013483 (2015).","journal-title":"Lung Cancer"},{"issue":"6","key":"15056_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cllc.2020.04.004","volume":"21","author":"XY Li","year":"2020","unstructured":"Li, X. Y. et al. Analysis of progression patterns and failure sites of patients with metastatic lung adenocarcinoma with EGFR mutations receiving First-line treatment of tyrosine kinase inhibitors. Clin. Lung Cancer. 21 (6), 534\u2013544 (2020).","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"15056_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1186\/s12885-021-08983-2","volume":"21","author":"T Miyawaki","year":"2021","unstructured":"Miyawaki, T. et al. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer. 21 (1), 1247 (2021).","journal-title":"BMC Cancer"},{"issue":"4","key":"15056_CR15","doi-asserted-by":"publisher","first-page":"e020690","DOI":"10.1136\/bmjopen-2017-020690","volume":"8","author":"J Conibear","year":"2018","unstructured":"Conibear, J. et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open. 8 (4), e020690 (2018).","journal-title":"BMJ Open."},{"key":"15056_CR16","doi-asserted-by":"publisher","first-page":"109681","DOI":"10.1016\/j.radonc.2023.109681","volume":"184","author":"P Peng","year":"2023","unstructured":"Peng, P. et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 184, 109681 (2023).","journal-title":"Radiother Oncol."},{"issue":"17","key":"15056_CR17","doi-asserted-by":"publisher","first-page":"e42297","DOI":"10.1097\/MD.0000000000042297","volume":"104","author":"O Illini","year":"2025","unstructured":"Illini, O. et al. Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on brigatinib combined with local therapy. Med. (Baltim). 104 (17), e42297 (2025).","journal-title":"Med. (Baltim)."},{"key":"15056_CR18","doi-asserted-by":"crossref","unstructured":"Elamin, Y. et al. OA22.04 BRIGHTSTAR local consolidative therapy with brigatinib in tyrosine kinase Inhibitor-Na\u00efve ALK-Rearranged metastatic NSCLC. J. Thorac. Oncol. 18(11),  S96 (2023).","DOI":"10.1016\/j.jtho.2023.09.109"},{"issue":"3","key":"15056_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1055\/s-0039-3400290","volume":"41","author":"P Lang","year":"2020","unstructured":"Lang, P., Gomez, D. R. & Palma, D. A. Local ablative therapies in oligometastatic NSCLC: new data and new directions. Semin Respir Crit. Care Med. 41 (3), 369\u2013376 (2020).","journal-title":"Semin Respir Crit. Care Med."},{"key":"15056_CR20","doi-asserted-by":"crossref","unstructured":"Chen, Y. H., Ho, U. C. & Kuo, L. T. Oligometastatic disease in Non-Small-Cell lung cancer: an update. Cancers (Basel) 14(5), 1350 (2022).","DOI":"10.3390\/cancers14051350"},{"issue":"4","key":"15056_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.23.02075","volume":"43","author":"H Sun","year":"2025","unstructured":"Sun, H. et al. Thoracic radiotherapy improves the survival in patients with EGFR-Mutated Oligo-Organ metastatic Non-Small cell lung cancer treated with epidermal growth factor Receptor-Tyrosine kinase inhibitors: A multicenter, randomized, controlled, phase III trial. J. Clin. Oncol. 43 (4), 412\u2013421 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"15056_CR22","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.2217\/fon-2022-0491","volume":"18","author":"X Li","year":"2022","unstructured":"Li, X. et al. Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis. Future Oncol. 18 (27), 3055\u20133065 (2022).","journal-title":"Future Oncol."},{"issue":"2","key":"15056_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijrobp.2023.09.009","volume":"118","author":"Y Meng","year":"2024","unstructured":"Meng, Y. et al. Treatment-Related pneumonitis of EGFR tyrosine kinase inhibitors plus thoracic radiation therapy in patients with Non-Small cell lung cancer: A systematic review and Meta-Analysis. Int. J. Radiat. Oncol. Biol. Phys. 118 (2), 415\u2013426 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"12","key":"15056_CR24","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","volume":"14","author":"AC Dingemans","year":"2019","unstructured":"Dingemans, A. C. et al. Definition of synchronous oligometastatic Non-Small cell lung Cancer-A consensus report. J. Thorac. Oncol. 14 (12), 2109\u20132119 (2019).","journal-title":"J. Thorac. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15056-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15056-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15056-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:06:12Z","timestamp":1757408772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15056-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15056"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15056-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"This study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University, China (Reference No. QYFYWZLL29747). All experiments involving human participants were conducted in accordance with the Declaration of Helsinki and institutional guidelines and regulations. Given the retrospective nature of this study, the requirement for informed consent was waived by the Ethics Committee of the Affiliated Hospital of Qingdao University.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"30650"}}